Literature DB >> 31542427

Dammarane sapogenins alleviates depression-like behaviours induced by chronic social defeat stress in mice through the promotion of the BDNF signalling pathway and neurogenesis in the hippocampus.

Ning Jiang1, Jing-Wei Lv1, Hai-Xia Wang1, Cong Lu2, Qiong Wang3, Tian-Ji Xia1, Yu Bao1, Shan-Shan Li3, Xin-Min Liu4.   

Abstract

Chronic social defeat stress (CSDS) is a widely used behavioural paradigm of psychosocial stress that can be used to research the pathogenesis of depression and seek antidepressant drugs. Dammarane sapogenins (DS), the deglycosylated product of ginsenosides, has a wide range of biological activities, including immunomodulatory, antifatigue, antitumour and antidepressant activities. However, whether DS has antidepressant-like effects in a CSDS mouse model remains unknown. Therefore, the present study was conducted to evaluate the antidepressant properties of DS in CSDS mice and its underlying mechanisms. The results showed that the oral administration of DS (40 and 80 mg/kg) increased the time spent in the interaction zone in the social interaction test and the sucrose intake in the sucrose preference test, decreased the latency in the novelty-suppressed feeding test, and reduced the immobility time in both the tail suspension test and forced swimming test. Biochemical analyses of brain tissue and serum showed that DS treatment significantly decreased serum corticosterone levels and enhanced brain monoamine neurotransmitter levels in CSDS mice. In addition, an impairment in hippocampal neurogenesis that paralleled a reduced BDNF level in the hippocampus was observed in the mice that were subjected with CSDS for 3 weeks, while treatment with DS reversed these changes. Moreover, DS treatment significantly upregulated BDNF, pTrkB/TrkB, pAkt/Akt, pPI3K/PI3K, pCREB/CREB, pERK1/2/ERK1/2 and pmTOR/mTOR protein expression in the hippocampus. In conclusion, our results showed that DS exerts antidepressant-like effects in mice with CSDS-induced depression, that the effects may be mediated by the normalization of monoamine neurotransmitter levels, the prevention of HPA axis dysfunction and the impairment of hippocampal neurogenesis, and that this occurs partly through the ability of DS to enhance BDNF expression by increasing the TrkB/CREB/ERK pathway and the PI3K/AKT/mTOR pathway.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  BDNF; Chronic social defeat stress; Dammarane sapogenins; Depression; Mice; Neurogenesis

Year:  2019        PMID: 31542427     DOI: 10.1016/j.brainresbull.2019.09.007

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  5 in total

1.  Identifying Antidepressant Effects of Brain-Derived Neurotrophic Factor and IDO1 in the Mouse Model Based on RNA-Seq Data.

Authors:  Jing Ren; Chenyang Li; Songren Wei; Yanjun He; Peng Huang; Jiangping Xu
Journal:  Front Genet       Date:  2022-05-30       Impact factor: 4.772

Review 2.  Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression.

Authors:  Haixia Wang; Yi He; Zuoli Sun; Siyu Ren; Mingxia Liu; Gang Wang; Jian Yang
Journal:  J Neuroinflammation       Date:  2022-06-06       Impact factor: 9.587

Review 3.  Hippocampal regenerative medicine: neurogenic implications for addiction and mental disorders.

Authors:  Lee Peyton; Alfredo Oliveros; Doo-Sup Choi; Mi-Hyeon Jang
Journal:  Exp Mol Med       Date:  2021-03-30       Impact factor: 8.718

4.  Social defeat: Vagal reduction and vulnerability to ventricular arrhythmias.

Authors:  Charly Brouillard; Pascal Carrive; Caroline Sévoz-Couche
Journal:  Neurobiol Stress       Date:  2020-08-03

5.  Antidepressant and Anxiolytic-Like Effects of the Stem Bark Extract of Fraxinus rhynchophylla Hance and Its Components in a Mouse Model of Depressive-Like Disorder Induced by Reserpine Administration.

Authors:  Yu Ri Kim; Bo-Kyung Park; Chang-Seob Seo; No Soo Kim; Mi Young Lee
Journal:  Front Behav Neurosci       Date:  2021-06-17       Impact factor: 3.558

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.